Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$2.32M$2.32M+48.2% vs Q1 2019 Net Income-$816.00K-$816.00KN/M vs Q1 2019 EPS Diluted-$0.01-$0.01N/M vs Q1 2019 Gross Profit$1,236,000+135.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$653,000N/M Free Cash Flowderived-$751,000N/M Margins · derivedGross margin53.4%+19.8 pt vs Q1 2019
Operating margin-36.1%+61.1 pt vs Q1 2019
Net margin-35.2%+61.3 pt vs Q1 2019
ended Sep 30, 2019 · filed Nov 13, 2019 · 44 d after period end